Summary

This expert panel gives recommendations for diagnosis and treatment of chronic myeloid leukemia. They are based on the European Leukemia Net and the most recent literature. When ever possible, patients with newly diagnosed chronic myeloid leukemia should be treated within a prospective multicenter trial. A correct diagnosis, risk assessment of the disease and evaluation of an allogeneic transplantation are essential. Outside a clinical trial the recommended treatment for patients in chronic phase is imatinib mesylate at an initial dose of 400 mg daily p.o. Response must be assessed at predefined regular intervals. Depending on the risk profile, the response to the treatment, patient’s preference and cost considerations therapy should be modifie